CA
NZ
UK
AU
IND
US
…
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Revive Therapeutics Ltd is a Canada-listed biotechnology company developing small-molecule and psychedelic-derived treatments for infectious, inflammatory and mental health conditions. Long-term growth could be supported by clinical program progress, intellectual property development and strategic collaborations that help advance commercialization. Investors may find exposure to a diversified pipeline appealing for potential upside if programs advance.
The primary risks are early-stage clinical and regulatory uncertainty, limited revenue history and likely need for additional financing that could dilute shareholders, alongside competitive and execution challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -11.01M | -5.62M | -6.32M | -17.81M | -20.12M |
| Net income | -11.01M | -5.62M | -6.32M | -17.81M | -20.12M |
| Selling general administrative | 1.40M | 2.18M | 1.94M | 2.68M | 11.87M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Ebit | - | - | - | -17.78M | -18.57M |
| Ebitda | - | - | - | -17.74M | -20.04M |
| Operating income | -1.65M | -5.61M | -6.39M | -17.87M | -20.30M |
| Interest expense | 0.00M | 0.02M | 0.04M | 0.06M | 0.08M |
| Interest income | 0.00M | 0.00M | 0.07M | 0.06M | 0.18M |
| Net interest income | -0.00M | 0.04M | 0.06M | 0.05M | 0.02M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 1.65M | 3.29M | 5.52M | 17.83M | 18.59M |
| Total other income expense net | -9.36M | -2.37M | -0.86M | -0.03M | -1.54M |
| Net income from continuing ops | -11.01M | -5.62M | -6.32M | -17.81M | -20.12M |
| Net income applicable to common shares | - | -5.62M | -6.32M | -17.81M | -20.12M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 0.21M | 10.64M | 14.25M | 17.07M | 29.81M |
| Intangible assets | - | 9.38M | 11.72M | 12.50M | 12.50M |
| Other current assets | - | 0.05M | 0.05M | - | - |
| Total liab | 3.66M | 3.40M | 3.60M | 4.46M | 1.00M |
| Total stockholder equity | -3.46M | 7.23M | 10.65M | 12.60M | 28.81M |
| Common stock | - | 47.50M | 45.98M | 43.11M | 42.43M |
| Capital stock | 47.70M | 47.50M | 45.98M | 43.11M | 42.43M |
| Retained earnings | -77.20M | -63.78M | -47.98M | -54.25M | -36.44M |
| Other liab | - | - | - | 0.08M | 0.07M |
| Other assets | - | - | - | 0.15M | 0.26M |
| Cash | 0.01M | 0.77M | 2.09M | 3.92M | 16.60M |
| Cash and equivalents | - | 0.77M | 2.09M | 3.92M | 16.60M |
| Total current liabilities | 3.51M | 3.32M | 3.44M | 4.17M | 0.60M |
| Net debt | 0.05M | - | - | - | - |
| Short term debt | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Short long term debt total | - | - | - | - | 0.33M |
| Other stockholder equity | - | - | - | 11.34M | 11.43M |
| Property plant equipment | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total current assets | 0.07M | 1.14M | 2.35M | 4.16M | 16.79M |
| Long term investments | 0.14M | 0.12M | 0.16M | 0.25M | 0.25M |
| Net tangible assets | - | - | - | 0.10M | 16.31M |
| Short term investments | - | - | - | - | 0.00M |
| Net receivables | - | - | - | 0.19M | 0.13M |
| Long term debt | 0.07M | 0.00M | 0.06M | 0.06M | 0.06M |
| Accounts payable | 2.65M | 2.58M | 2.66M | 3.92M | 0.44M |
| Non current assets total | 0.14M | 9.50M | 11.90M | 12.90M | 13.01M |
| Capital lease obligations | 0.00M | 0.03M | 0.16M | 0.27M | 0.36M |
| Long term debt total | - | 0.00M | 0.09M | 0.22M | 0.33M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.03M | 0.00M | - | 0.00M | 0.28M |
| Change to liabilities | - | - | - | 3.58M | 0.21M |
| Total cashflows from investing activities | - | - | - | 0.00M | -2.72M |
| Net borrowings | 0.04M | -0.04M | 0.00M | -0.15M | -0.13M |
| Total cash from financing activities | 0.04M | 1.98M | 4.20M | 0.38M | 26.24M |
| Change to operating activities | - | - | - | -0.03M | 0.50M |
| Net income | -11.01M | -5.62M | -6.32M | -17.81M | -20.12M |
| Change in cash | -0.76M | -1.31M | -1.83M | -12.68M | 15.22M |
| Begin period cash flow | 0.77M | 2.09M | 3.92M | 16.60M | 1.38M |
| End period cash flow | 0.01M | 0.77M | 2.09M | 3.92M | 16.60M |
| Total cash from operating activities | -0.77M | -3.29M | -6.03M | -13.06M | -8.31M |
| Issuance of capital stock | 0.00M | 2.02M | 4.20M | 0.38M | 28.67M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Other cashflows from investing activities | - | - | - | 0.00M | 0.28M |
| Sale purchase of stock | - | 2.02M | 4.20M | 0.38M | 28.67M |
| Other cashflows from financing activities | - | - | - | 0.15M | -2.30M |
| Change to netincome | - | - | - | 1.20M | 11.11M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 3.00M |
| Change in working capital | 0.60M | -0.19M | -0.75M | 3.54M | 0.71M |
| Stock based compensation | 0.12M | 0.14M | 0.00M | 1.04M | 8.57M |
| Other non cash items | 0.20M | -0.02M | 0.18M | 0.14M | 0.98M |
| Free cash flow | -0.77M | -3.29M | -6.03M | -13.06M | -11.31M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| RVV Revive Therapeutics Ltd |
0.01 33.33% |
0.02 | - | - | - | 0.73 | -2.39 |
| GTII Green Thumb Industries Inc |
0.04 0.43% |
9.28 | 14.70 | 34.84 | 1.91 | 0.86 | 3.95 |
| CL Cresco Labs Inc |
0.02 2.67% |
0.77 | - | 105.26 | 0.70 | 0.99 | 42.44 |
| JUSH Jushi Holdings Inc |
-0.01 1.59% |
0.62 | - | 17.86 | 0.52 | 0.69 | 9.56 |
| GRIN Grown Rogue International Inc |
-0.01 2.08% |
0.47 | 23.50 | - | 3.62 | 4.10 | 11.19 |
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Frank | Chairman & CEO | 1961 |
| Mr. Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA | Chief Financial Officer | 1971 |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Scientific Officer Consultant | 1950 |
| Dr. Onesmo Mpanju Ph.D. | Chief Regulatory Affairs Consultant | NA |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Scientific Officer Consultant | 1951 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.26%
Communication Services
-0.18%
Consumer Cyclical
-0.36%
Consumer Defensive
+0.07%
Energy
-0.01%
Financial Services
-0.26%
Financials
-2.20%
Healthcare
-0.55%
Industrials
-0.08%
Real Estate
-0.33%
Technology
-0.70%
Utilities
-0.41%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...